ERBB2 and breast cancer: The lack of difference in the pCR rate between HER2 IHC 2+ and 3+ tumors may imply a strong oncogenic addiction of HER2-positive breast cancer and the efficacy of dual HER2 blockade in ER-negative breast cancer.